Technical analysis of Alector, Inc. (ALEC): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders.
Price Performance
| 1 month | -12.67% |
| 3 months | +10.29% |
| Year-to-date | +23.72% |
| 1 year | -34.58% |
| 3 years | -68.52% |
| 5 years | -92.80% |
52-Week Range
| 52-week High | $3.40 |
| 52-week Low | $1.09 |
| Avg Volume (90d) | 1.0M |
Technical Indicators
| SMA 50 | $1.93 |
| SMA 200 | $1.96 |
| Beta | 0.58 |
| 30-day Volatility (annualised) | 120.2% |
| Price vs SMA 50 | +0.1% |
| Price vs SMA 200 | -1.3% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $1.47 | |
| 2025-11 | $1.33 | -9.5% |
| 2025-12 | $1.56 | +17.3% |
| 2026-01 | $1.89 | +21.2% |
| 2026-02 | $2.43 | +28.6% |
| 2026-03 | $2.15 | -11.5% |
| 2026-04 | $2.37 | +10.2% |
| 2026-05 | $2.16 | -8.9% |
| 2026-06 | $2.01 | -6.9% |
| 2026-07 | $1.51 | -24.9% |
| 2026-08 | $2.26 | +49.7% |
| 2026-09 | $1.93 | -14.6% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | | |
| 2026-09-14 | | $563M |
| 2026-09-14 | | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $0.20 | $23M |
| 2026-09-14 | | |
Price
| Price | $1.93 |
| Market Cap | $214M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -18.68 |
| EV / EBITDA | -1.95 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | -3.29 |
| Current Ratio | 5.26 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -5.04 |